Special Issue

JC Polyomavirus

Message from the Guest Editors

We invite you to contribute to a Special Issue on JC polyomavirus (JCPyV).

JCPyV is a small, nonenveloped, circular double-stranded DNA virus first isolated in 1971, linked to progressive multifocal leukoencephalopathy (PML). PML is a rare, often fatal disease of the central nervous system, historically described in patients with hematologic malignancies. The HIV pandemic in the 1980s caused a significant rise in PML cases, which later decreased with antiretroviral therapy. Recently, immunomodulatory therapies for chronic diseases and transplants have led to iatrogenic PML. Currently, no antiviral treatments exist for JCPyV infection.

PML is associated with neurotropic variants that have rearrangements in the JCPyV genomic regulatory non-coding control region (NCCR). The mechanisms of these variants are not well understood, and the rarity of the disease limits large cohort studies.

This Special Issue aims to compile current knowledge on JCPyV and guide future research. We welcome research papers and reviews on its pathophysiology, molecular biology, virus–host interactions, epidemiology, and antiviral development.

We look forward to your contributions.

Guest Editors

Dr. Sébastien Lhomme

- 1. Toulouse University Hospital, Purpan Hospital, Virology Department, Toulouse 31300, France
- 2. Inserm UMR 1291, CNRS UMR5051, Université Toulouse III, Toulouse, France

Dr. Anne-Sophie L'Honneur

Department of Virology, Cochin Hospital, AP-HP, 75014 Paris, France

Deadline for manuscript submissions

30 September 2025



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/210851

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAq, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).